Manish Goel

About Manish Goel

SEBI Registered Research Analyst • Chartered Accountant

377 Articles Published

Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

Facebook X (Twitter) Instagram YouTube LinkedIn

April 18, 2026

Infographic: 'Rights Issues' bar chart showing yearly values FY20–FY25, with FY25 in green and values 28, 26, 22, 18, 14, 11.

Rights Issues: When Fresh Capital Helps Minority Shareholders and When It Hurts Them

A rights issue can preserve minority ownership or quietly dilute it. The difference lies in why the company needs money, how management behaves, and whether investors understand their rights entitlement before it lapses.

April 18, 2026

Hero header for an article on Mental Accounting Bias showing a four‑panel diagram: top-left 'Lucky' (gray), top-right 'Discipined Investor' (green), bottom-left 'Confused' (light gray), bottom-right 'Bias-Trapped' (orange); dark blue page with subtitle.

Mental Accounting Bias: The Silent Wealth Destroyer That Makes Indian Investors Treat ‘Profits’ Differently From ‘Capital’ — How Richard Thaler’s Nobel-Winning Insight Explains Why Retail Investors Underperform the Sensex Year After Year

Mental accounting — the Nobel-winning behavioural finance concept by Richard Thaler — explains why Indian investors gamble their 'profits' in F&O while treating 'original capital' conservatively. Learn how to recognise and defeat this silent wealth destroyer, with live Sensex and Titan Biotech data.

April 18, 2026

Bar chart: Segment Reporting values from FY20 to FY25, with FY20=28, FY21=26, FY22=22, FY23=18, FY24=14, FY25=11; FY25 bar is green.

Segment Reporting: The Hidden Disclosure in Indian Annual Reports That Reveals True Business Quality — How Smart Value Investors Decode Ind AS 108 to Find Multibaggers the Crowd Misses

MGMANISH GOEL PMS☰ HomePast PerformanceServicesMedia & PressBlogsAwards WhatsApp · 7380122211 VALUE INVESTING · BLOG Segment Reporting: The Hidden Disclosure in Indian Annual Reports That Reveals True […]

April 18, 2026

Contingent Liabilities

Titan Biotech's FY25 contingent liability disclosure stands at just ₹7.78 Cr — a forensic gold standard 5.08% of net worth versus the 15–50% Indian small-cap norm. Here is the deep-dive every value investor must read.